Hayashi Toshihide, Joki Nobuhiko, Tanaka Yuri, Iwasaki Masaki, Kubo Shun, Asakawa Takasuke, Matsukane Ai, Takahashi Yasunori, Imamura Yoshihiko, Hirahata Koichi, Hase Hiroki
Division of Nephrology, Toho University Ohashi Medical Center, 2-17-6 Ohashi, Meguro-Ku, Tokyo, 153-8515, Japan.
Division of Dialysis, Nissan Tamagawa Hospital, Tokyo, Japan.
J Bone Miner Metab. 2015 Nov;33(6):674-83. doi: 10.1007/s00774-014-0631-5. Epub 2015 Feb 18.
The World Health Organization Fracture Risk Assessment Tool (FRAX(®)) was recently developed to estimate the 10-year absolute risk of osteoporotic fracture among the general population. However, the evidence for its use in chronic kidney disease patients has been lacking, and the association between the FRAX(®) and mortality is unknown. Therefore, a hospital-based, prospective, cohort study was conducted to evaluate the predictive ability of the FRAX(®) for mortality in hemodialysis patients. A total of 252 patients who had been started on maintenance hemodialysis, 171 men and 81 women, with a mean age of 67 ± 14 years, was studied. The endpoint was defined as all-cause death. The Cox proportional hazards model was used to calculate hazard ratios and 95 % confidence intervals. During the mean follow-up period of 3.4 ± 2.7 years, 61 deaths occurred. The median (interquartile range) of the FRAX(®) for major osteoporotic fracture was 6.9 (4.6-12.0) % in men and 19.0 (7.6-33.0) % in women. Cumulative survival rates at 5 years after starting dialysis, with the FRAX(®) levels above and below the median, were 51.9 and 87.9 %, respectively, in men and 67.4 and 83.7 %, respectively, in women. Overall, in men, the multivariate Cox regression analyses revealed that the log-transformed FRAX(®) remained an independent predictor of death after adjusting by confounding variables. However, in women, the significant association between the FRAX(®) value and the outcome was eliminated if age was put into these models. Among Japanese hemodialysis patients, the FRAX(®) seems to be useful for predicting death, especially in men.
世界卫生组织骨折风险评估工具(FRAX(®))最近被开发出来,用于估计普通人群中骨质疏松性骨折的10年绝对风险。然而,缺乏其在慢性肾病患者中应用的证据,且FRAX(®)与死亡率之间的关联尚不清楚。因此,开展了一项基于医院的前瞻性队列研究,以评估FRAX(®)对血液透析患者死亡率的预测能力。共研究了252例开始维持性血液透析的患者,其中男性171例,女性81例,平均年龄67±14岁。终点定义为全因死亡。采用Cox比例风险模型计算风险比和95%置信区间。在平均3.4±2.7年的随访期内,发生了61例死亡。男性主要骨质疏松性骨折的FRAX(®)中位数(四分位间距)为6.9(4.6 - 12.0)%,女性为19.0(7.6 - 33.0)%。透析开始后5年,FRAX(®)水平高于和低于中位数的男性累积生存率分别为51.9%和87.9%,女性分别为67.4%和83.7%。总体而言,在男性中,多变量Cox回归分析显示,经混杂变量调整后,对数转换后的FRAX(®)仍然是死亡的独立预测因素。然而,在女性中,如果将年龄纳入这些模型,FRAX(®)值与结局之间的显著关联就会消除。在日本血液透析患者中,FRAX(®)似乎对预测死亡有用,尤其是在男性中。